Evidence suggests that patients with relapsed or refractory indolent lymphoma treated with PI3K inhibitor exhibit an ORR of 59% [37], also significantly prolonged progression-free survival for patients harbor PIK3CA mutation in advanced breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.